Watch our live demo from the CSD Launch on February 15, 2022.
- Illuminate the Science - Webinar 1: In honor of men's health month, we focused on using the database to gain insights on the research on EPA and DHA supplementation and cardiovascular disease and other conditions in men. Passcode: q+9a28bx. June 23, 2022.
- Illuminate the Science Webinar 2: This webinar focused on cognitive health and brain health, spelling out the different dimensions, challenges and opportunities related to the topic and their relationships to omega-3s. There are many cognitive tests used to measure outcomes in omega-3 studies and this creates challenges in streamling intake recommendations for brain health. Passcode: SLS%Jr69. December 7, 2022.
- This report shows the strength of the evidence on arteriosclerosis and EPA+DHA omega-3s through the evaluation of interventional studies, also providing a use case for GOED's unique Clinical Study Database (CSD).
- This report covers research specific to EPA+DHA across 90% of all abstracts published to date and across interventional studies published to the end of 2019. This report was published in September 2022.
- GOED members can access this report by signing into their GOED member accounts and searching for "Scientific Reports". Non-GOED members can contact email@example.com for more information.
Did you know we also have two reports on skin health? We have one report on Psoriasis and one report on Dermatitis published in 2022. We also have a scoping review on brain health published in 2023, and a *new" report on the evidence on exercise and exercise outcomes through the evaluation of interventional studies published in 2023.
Email firstname.lastname@example.org for more information.
Methods Behind the GOED Clinical Study Database
We published a paper in August 2022 describing the methods behind the development of the GOED Clinical Study Database. "Development of a novel database to review and assess the clinical effects of EPA and DHA omega-3 fatty acids." Aldo A Bernasconi, Allison M Wilkin, Kaitlin Roke, Adam Ismail. Prostaglandins, Leukotrienes and Essential Fatty Acids. Volume 183, 102458, ISSN 0952-3278. 2022."
Abstract: Due to their multiple mechanisms of biological action, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been the focus of ongoing active research for decades. In spite of the resulting body of knowledge, there remain significant gaps in our understanding of EPA/DHA health effects. Further, the volume of existing research makes it challenging to conduct systematic investigations to identify or resolve those gaps. The purpose of this article is to introduce the GOED Clinical Study Database (CSD), a comprehensive, manually-curated relational database that catalogs this research.
Review using the GOED Clinical Study Database
We published a paper in January 2023 describing the complexity of the science surrounding cognitive health. "New perspectives on randomized controlled trails with omega-3 fatty acid supplements and cognition: A scoping review" B. Andriambelo, M. Stiffel, K. Roke, M. Plourde. Ageing Research Reviews. Volume 85, 101835, ISSN 1568-1637. 2023."
Abstract: Long chain polyunsaturated omega-3 fatty acids (n-3 FA), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are known to be important components in a healthy diet and contribute to healthy functioning of the heart and the brain, among other organs. Although there are epidemiological studies on the strong relationship between fish or n-3 FA consumption and lower risk of cognitive decline, results from randomized controlled trials (RCTs) are less consistent. Here, we performed a scoping review on RCTs with n-3 FA supplementation where cognition was evaluated. Seventy-eight RCTs published before April 2022 were included in this review. Among these RCTs, 43.6% reported a positive cognitive outcome after the consumption of n-3 FA compared to the placebo. However, there was a large diversity of populations studied (age ranges and health status), wide range of doses of EPA + DHA supplemented (79 mg/day – 5200 mg/day) and a multitude of tests evaluating cognition, mainly diagnostic tests, that were used to assess cognitive scores and overall cognitive status. RCTs were thereafter categorized into non-cognitively impaired middle-aged adults (n = 24), non-cognitively impaired older adults (n = 24), adults with subjective memory complaints (n = 14), adults with mild cognitive impairments (MCI, n = 9) and people with diagnosed dementia or other cognitive changes (n = 7). Among these categories, 66.7% of RCTs conducted with MCI adults reported a positive cognitive outcome when supplemented with n-3 FA vs. the placebo. Therefore, this scoping review provides rationale and questions to a) strengthen the design of future RCTs with n-3 FA for cognitive outcomes, and b) generate more informative data to support clinicians in their practice in assessing cognition before and after a nutritional intervention.
Our database is still new and we are working hard to gather information from our subscribers on how and why they are using this tool.
If you are interested in doing a project with us, please contact our Director of Scientific Communication and Outreach email@example.com.
Case Study 1: Using the GOED Clinical Study Database (CSD) to Support the Preparation of a Health Claim Petition. November 7, 2022.
In 2014, GOED commissioned a meta-analysis reviewing the evidence for intake of EPA and DHA omega-3s on blood pressure in randomized controlled trials (RCTs). The results of this publication formed the basis for the US Food and Drug Administration’s (FDA) 2019 ruling allowing a qualified health claim that consuming EPA and DHA intake may reduce the risk of hypertension and coronary heart disease. As part of this project, an extensive review of the literature was undertaken. Since this was before the existence of the CSD, we thought it would be interesting to show how the CSD could have been used to compile the research for the project. Click here or the image below to view our video on the topic.
Case Study 2: Using the GOED Clinical Study Database (CSD) for a systematic review or meta-analysis.
One of the most important benefits of using the CSD is how it can help to save people time. The database research team reviews all abstracts that appeared to be about EPA and DHA, and only keeps those in the database that were relevant. This is a hugely time consuming process that the research groups would undertake. What used to take months now takes minutes. A typical systematic review and meta-analysis project may take anywhere from several months to a year to complete depending on how many people were working on the project. The CSD uses PubMed as its background database. So if a research group wants to use the CSD, they may also choose to cross-reference with an additional academic database. Click here or the image below to watch our video on this topic.
We are working to gather information from our subscribers on their experiences using this tool. Thank you to those who have contributed so far.